Apple Earnings Call: Key Takeaways
Apple reported record Q4 revenue of $114.5 billion, up 12%, driven by iPhone and Mac growth despite significant memory cost headwinds and supply constraints.
- Call
- Nov 2, 2026, 5:00 PM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Filing type
Alerts
Time
21,439 alerts with these filters
Apple reported record Q4 revenue of $114.5 billion, up 12%, driven by iPhone and Mac growth despite significant memory cost headwinds and supply constraints.
Travere achieved record quarterly revenue of $220.2 million, driven by Filspari's expansion into FSGS, though management faces a CEO transition and increased competition in the IgA nephropathy market.
ARCH Venture Fund X L.P., 10% Owner, bought 1,333,333 shares of Aspen Neuroscience, Inc. at $15.00 a share, worth $20M in total on Nov 2, 2026. Shares held after the trade: 1,200,000.
ARCH Venture Partners XIV L.P., 10% Owner, bought 1,200,000 shares of Aspen Neuroscience, Inc. at $15.00 a share, worth $18M in total on Nov 2, 2026. Shares held after the trade: 1,200,000.
Hamilton Lane Advisors LLC bought 1,824,686 shares of Hamilton Lane Venture Capital & Growth Fund at $12.99 to $20.50 a share (average $20.02) in 2 transactions, worth $36.5M in total between Jul 28, 2025 and Oct 29, 2026. Shares held after the trade: 2,396,201 (+247.8%).
George Kurtz, President and CEO, sold 19,800 shares of CrowdStrike Holdings, Inc. at $246.13 to $267.66 a share (average $255.10) in 29 transactions, worth $5.05M in total between Oct 29, 2026 and Oct 30, 2026. Shares held after the trade: 7,341,704 (-0.0%).
George Kurtz, President and CEO, sold 200 shares of CrowdStrike Holdings, Inc. at $261.60 a share, worth $52.3K in total on Oct 30, 2026. Shares held after the trade: 7,341,504 (-0.0%).
Julie Winkler, Sr MD Chief Commercial Officer, sold 10,079 shares of CME Group Inc. at $305.15 a share, worth $3.08M in total on Nov 2, 2026. Shares held after the trade: 21,482 (-31.9%).
Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).
Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).
Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).
Vincent Drouillard, General Counsel, sold 10,000 shares of AerCap Holdings N.V. at $158.14 a share, worth $1.58M in total on Oct 29, 2026. Shares held after the trade: 81,623 (-10.9%).
Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).
Kurt James Wolf, President & CEO, sold 201,517 shares of Pitney Bowes Inc at $16.23 to $17.45 a share (average $16.54) in 4 transactions, worth $3.33M in total between Oct 29, 2026 and Nov 2, 2026. Shares held after the trade: 73,184 (-15.6%).
Peuch Olivier Le, CEO, sold 25,000 shares of Slb Limited at $52.90 a share, worth $1.32M in total on Nov 2, 2026. Shares held after the trade: 1,246,328 (-2.0%).
Christopher M. Mulhall, VP - CAO, sold 26,055 shares of Fortive Corp at $65.56 to $65.57 a share (average $65.56) in 2 transactions, worth $1.71M in total on Oct 30, 2026. Shares held after the trade: 15,597 (-34.2%).
Peter C. Underwood, SVP - CLO, sold 48,442 shares of Fortive Corp at $64.60 a share, worth $3.13M in total on Oct 30, 2026. Shares held after the trade: 79,118 (-38.0%).
Steven Hershkowitz, EVP & Chief Revenue Officer, sold 42,482 shares of Rimini Street, Inc. at $4.98 a share, worth $211K in total on Nov 2, 2026. Shares held after the trade: 186,992 (-18.5%).
Thomas Winter bought 10,000 shares of Rush Street Interactive, Inc. at $11.83 a share, worth $118K in total on Nov 2, 2026. Shares held after the trade: 30,497 (+48.8%).
BioMarin achieved record $1B+ quarterly revenue but lowered full-year guidance due to $70M in international order timing shifts and Middle East geopolitical headwinds, despite strong underlying demand and accelerated Amicus cost synergies.
Stephen P. Ewald, General Counsel & Corp. Secy., sold 1,245 shares of Medpace Holdings, Inc. at $690.00 a share, worth $859K in total on Oct 29, 2026. Shares held after the trade: 19,098 (-6.1%).
Robert Edward Moritz Jr. bought 236 shares of Northern Trust Corp at $169.07 a share, worth $39.9K in total on Oct 30, 2026. Shares held after the trade: 8,636 (+2.8%).
Robert I. Blum, President & CEO, sold 7,500 shares of Cytokinetics Inc at $62.81 a share, worth $471K in total on Nov 2, 2026. Shares held after the trade: 278,544 (-2.6%).
Backblaze delivered a strong Q3 beat and raise, driven by 47% B2 revenue growth and significant AI infrastructure momentum, including early data loading from a major NeoCloud customer.
Inspire Medical reported a 7.9% year-over-year revenue decline due to $120 million in coding headwinds, while focusing on a 2027 return to growth.
Josh Silverman, Director, sold 42,689 shares of Etsy Inc at $88.70 to $92.13 a share (average $92.03) in 2 transactions, worth $3.93M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 221,117 (-15.8%).
EverQuote delivered record Q3 results with 25% revenue growth, driven by a 70% surge in the home vertical and aggressive AI integration across its marketplace and internal engineering workflows.
Michael George Rosenbaum, CEO, sold 1,200 shares of Guidewire Software, Inc. at $160.16 a share, worth $192K in total on Nov 2, 2026. Shares held after the trade: 272,466 (-0.4%).
Henry B. Smith sold 4,893 shares of Axis Capital Holdings Ltd at $106.15 a share, worth $519K in total on Nov 2, 2026. Shares held after the trade: 41,454 (-10.6%).
Cerus delivered 10% revenue growth and positive Phase III Redis results, though regulatory timelines for the INT200 and CE Mark red cells have shifted later.